In this study, an integrative analysis of copy number profiling, gene expression microarray and Ki67-based AI response data was performed using data from samples in two cohorts of neoadjuvant AI therapy in postmenopausal patients with ER-positive early breast cancer. This evidence concerns the gene ESR1 and breast cancer.